Shanghai Kaibao Pharmaceutical (300039) — Net Asset Quality Index
Shanghai Kaibao Pharmaceutical (300039) has a Net Asset Quality Index of 91.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.96 Billion minus total liabilities of CN¥412.55 Million yields net assets of CN¥4.55 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 300039 financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanghai Kaibao Pharmaceutical Net Asset Quality Index Over Time (2006–2024)
This chart shows how Shanghai Kaibao Pharmaceutical's Net Asset Quality Index has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the index stands at 91.7%, representing net assets of CN¥4.55 Billion against total assets of CN¥4.96 Billion CNY. See 300039 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shanghai Kaibao Pharmaceutical (2006–2024)
The table below presents the year-by-year Net Asset Quality Index for Shanghai Kaibao Pharmaceutical from 2006 to 2024, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shanghai Kaibao Pharmaceutical market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.8% | CN¥4.10 Billion | CN¥4.52 Billion | CN¥415.45 Million | ▲ +2.7 pp |
| 2023 | 88.1% | CN¥4.03 Billion | CN¥4.58 Billion | CN¥546.82 Million | ▼ -0.2 pp |
| 2022 | 88.3% | CN¥3.76 Billion | CN¥4.26 Billion | CN¥498.24 Million | ▼ -2.4 pp |
| 2021 | 90.7% | CN¥3.04 Billion | CN¥3.36 Billion | CN¥310.90 Million | ▲ +1.1 pp |
| 2020 | 89.6% | CN¥2.58 Billion | CN¥2.88 Billion | CN¥298.96 Million | ▼ -0.8 pp |
| 2019 | 90.4% | CN¥2.57 Billion | CN¥2.84 Billion | CN¥273.01 Million | ▼ -0.1 pp |
| 2018 | 90.5% | CN¥2.49 Billion | CN¥2.75 Billion | CN¥262.26 Million | ▲ +2.2 pp |
| 2017 | 88.3% | CN¥2.37 Billion | CN¥2.68 Billion | CN¥314.26 Million | ▲ +1.2 pp |
| 2016 | 87.0% | CN¥2.20 Billion | CN¥2.53 Billion | CN¥327.61 Million | ▲ +4.4 pp |
| 2015 | 82.6% | CN¥2.01 Billion | CN¥2.43 Billion | CN¥421.16 Million | ▼ -6.4 pp |
| 2014 | 89.0% | CN¥1.88 Billion | CN¥2.12 Billion | CN¥232.72 Million | ▼ -1.7 pp |
| 2013 | 90.7% | CN¥1.61 Billion | CN¥1.77 Billion | CN¥164.72 Million | ▼ -0.2 pp |
| 2012 | 90.9% | CN¥1.42 Billion | CN¥1.56 Billion | CN¥142.29 Million | ▼ -1.0 pp |
| 2011 | 91.9% | CN¥1.33 Billion | CN¥1.45 Billion | CN¥117.97 Million | ▲ +1.6 pp |
| 2010 | 90.3% | CN¥1.24 Billion | CN¥1.37 Billion | CN¥133.39 Million | ▲ +5.1 pp |
| 2009 | 85.2% | CN¥1.15 Billion | CN¥1.35 Billion | CN¥199.20 Million | ▲ +30.0 pp |
| 2008 | 55.2% | CN¥126.92 Million | CN¥229.88 Million | CN¥102.95 Million | ▲ +7.6 pp |
| 2007 | 47.6% | CN¥76.96 Million | CN¥161.61 Million | CN¥84.64 Million | ▲ +13.5 pp |
| 2006 | 34.2% | CN¥37.24 Million | CN¥109.03 Million | CN¥71.80 Million | — |